Aspirin limits platelet TXA2-mediated suppression of T-cell immunity to prevent cancer metastasis
Authors:
- Kianoush SaberiKSKianoush Saberi
- Atieh OkhliAOAtieh Okhli
- Khorsid RigiKRKhorsid Rigi
- Seyed Amir BanikarimSBSeyed Amir Banikarim
- Sara Teihou JorshariSJSara Teihou Jorshari
- Niloofar KhosraviNKNiloofar Khosravi
- Zahed KarimiZKZahed Karimi
- Anna Ghorbani DoshantapehADAnna Ghorbani Doshantapeh
- Shahnaz SharifiSSShahnaz Sharifi
Open Access
- 22 April 2026
- journal article
- Published by Maad Rayan Publishing Company in Journal of Preventive Epidemiology
- Vol. 11 (2) , e39330
Abstract
Aspirin, a widely used non-steroidal anti-inflammatory drug, has shown promise in cancer prevention and reducing metastatic progression. This medication limits platelet thromboxane A2 (TXA2)-mediated suppression of T-cell immunity, thereby preventing cancer metastasis. Platelets, beyond their role in hemostasis, actively contribute to tumor progression and metastasis by various mechanisms, including shielding circulating tumor cells from immune surveillance and promoting their extravasation. One critical pathway involves platelet-derived TXA2, a potent lipid mediator that can directly suppress anti-tumor T-cell responses. TXA2 promotes immune evasion by inhibiting T-cell activation and proliferation, thus hindering the body’s ability to effectively eliminate cancerous cells. Aspirin’s well-known inhibitory effect on cyclooxygenase-1 (COX-1) is key here, as COX-1 is responsible for TXA2 synthesis in platelets. By irreversibly acetylating COX-1, aspirin effectively reduces TXA2 production. Then, the reduction in platelet TXA2 alleviates its immunosuppressive effects on T-cells, thereby restoring and enhancing anti-tumor immunity. The enhanced T-cell activity can then more effectively target and destroy circulating tumor cells, finally limiting the formation of secondary tumors and preventing metastasis.Keywords
This publication has 27 references indexed in Scilit:
- Aspirin prevents metastasis by limiting platelet TXA2 suppression of T cell immunityNature, 2025
- Long‐term use of low‐dose aspirin for cancer prevention: A 20‐year longitudinal cohort study of 1,506,525 Hong Kong residentsInternational Journal of Cancer, 2025
- The impact of platelets on the metastatic potential of tumour cellsHeliyon, 2024
- Aspirin and cancer treatment: systematic reviews and meta-analyses of evidence: for and againstBritish Journal of Cancer, 2023
- Platelet Contributions to the (Pre)metastatic Tumor MicroenvironmentSeminars in Thrombosis and Hemostasis, 2023
- Beyond COX-1: the effects of aspirin on platelet biology and potential mechanisms of chemopreventionCancer and Metastasis Reviews, 2017
- Expression of HLA Class I Antigen, Aspirin Use, and Survival After a Diagnosis of Colon CancerJAMA Internal Medicine, 2014
- Microenvironmental regulation of tumor progression and metastasisNature Medicine, 2013
- Nuclear translocation of nuclear factor of activated T cells (NFAT) as a quantitative pharmacodynamic parameter for tacrolimusCytometry Part A, 2013
- Mechanism of the irreversible inhibition of human cyclooxygenase-1 by aspirin as predicted by QM/MM calculationsJournal of Molecular Graphics and Modelling, 2013